Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib inKRAS-Mutant Pancreatic and Colorectal Cancer.
Weisner, J., Landel, I., Reintjes, C., Uhlenbrock, N., Trajkovic-Arsic, M., Dienstbier, N., Hardick, J., Ladigan, S., Lindemann, M., Smith, S., Quambusch, L., Scheinpflug, R., Depta, L., Gontla, R., Unger, A., Muller, H., Baumann, M., Schultz-Fademrecht, C., Gunther, G., Maghnouj, A., Muller, M.P., Pohl, M., Teschendorf, C., Wolters, H., Viebahn, R., Tannapfel, A., Uhl, W., Hengstler, J.G., Hahn, S.A., Siveke, J.T., Rauh, D.(2019) Cancer Res 79: 2367-2378
- PubMed: 30858154 
- DOI: 10.1158/0008-5472.CAN-18-2861
- Primary Citation of Related Structures:  
6HHF - PubMed Abstract: 
Aberrations within the PI3K/AKT signaling axis are frequently observed in numerous cancer types, highlighting the relevance of these pathways in cancer physiology and pathology. However, therapeutic interventions employing AKT inhibitors often suffer from limitations associated with target selectivity, efficacy, or dose-limiting effects ...